| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/26/2009 | US20090053222 Inhibitors of CD200 such as antibodies or antisense agents for treating cancer, tumor, leukemia |
| 02/26/2009 | US20090053221 Immune response enhancing glucan |
| 02/26/2009 | US20090053216 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of non-hodgkins lymphoma; immunotherapy |
| 02/26/2009 | US20090053215 Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| 02/26/2009 | US20090053210 Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| 02/26/2009 | US20090053203 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, obesity, cardiovascular, metabolic, neurodegenerative, gastrointestinal, autoimmune, rheumatological and infectious diseases; drug delivery |
| 02/26/2009 | US20090053199 Stable Dairy Components Effective for Fat Loss |
| 02/26/2009 | US20090053186 Therapy for primary and metastatic cancers |
| 02/26/2009 | US20090053184 Compositions comprising t cell receptors and methods of use thereof |
| 02/26/2009 | US20090053178 Use of herpes vectors for tumor therapy |
| 02/26/2009 | US20090053170 Human prostate cell lines in cancer treatment |
| 02/26/2009 | US20090053138 Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics |
| 02/26/2009 | US20090053137 Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof |
| 02/26/2009 | DE102007040243A1 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen 17beta-dehydrogenase type 1 Hydroxysteriod inhibitors for the treatment of hormone-dependent diseases |
| 02/26/2009 | CA2699988A1 Methods and compositions for treating cancers |
| 02/26/2009 | CA2697284A1 Therapeutic quinoline and naphthalene derivatives |
| 02/26/2009 | CA2697261A1 Treatment of lung cancer |
| 02/26/2009 | CA2697252A1 Calmodulin-binding peptides that reduce cell proliferation in cancer and smooth muscle proliferation diseases |
| 02/26/2009 | CA2697246A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5) |
| 02/26/2009 | CA2697043A1 Methods and compositions for treatment or prevention of radiation-induced fibrosis |
| 02/26/2009 | CA2696761A1 Human c-fms antigen binding proteins |
| 02/26/2009 | CA2696701A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | CA2696684A1 Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 02/26/2009 | CA2696597A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696591A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696579A1 Purine derivatives for use in the treatment of fab-related diseases |
| 02/26/2009 | CA2696472A1 6-thioxopyridazine derivatives |
| 02/26/2009 | CA2696200A1 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| 02/26/2009 | CA2696197A1 Pyridoneamide derivatives as focal adhesion kinase (fak) inhibitors and their use for the treatment of cancer |
| 02/26/2009 | CA2696027A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | CA2695452A1 Hdac inhibitors |
| 02/26/2009 | CA2693152A1 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 02/26/2009 | CA2691368A1 Method for activating regulatory t-cells |
| 02/26/2009 | CA2687028A1 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| 02/25/2009 | EP2028274A2 An antisense oligonucleotide against the TGF-beta2 gene |
| 02/25/2009 | EP2028190A1 Compounds and methods for therapy and diagnosis of lung cancer |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2027871A2 Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same |
| 02/25/2009 | EP2027867A1 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 02/25/2009 | EP2027866A1 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 02/25/2009 | EP2027853A2 Kinase inhibitors for treating cancers |
| 02/25/2009 | EP2027156A2 Hepatocyte growth factor (hgf) binding proteins |
| 02/25/2009 | EP2027154A2 Immunoglobulin constant region domains with enhanced stability |
| 02/25/2009 | EP2027131A1 39-desmethoxy-39-methyl derivatives of rapamycin. |
| 02/25/2009 | EP2027130A1 36 -des (3 -methoxy-4 -hydroxycyclohexyl) 36 - (3 -hydroxycycloheptyl) derivatives of rapamycin for the treatment of cancer and other disorders |
| 02/25/2009 | EP2027127A1 Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors |
| 02/25/2009 | EP2027126A2 Crystalline forms of 5-chloro-6- (2, 6-difluoro-4-[3- (methylamino) propoxy] phenyl)-n-((1s)-2, 2, 2,-trifluoro-1-methylethyl][1,2,4]triazolo [1,5-a]pyrimidin-7-amine salts |
| 02/25/2009 | EP2027115A1 Dioxaspiroketal derivatives, process for their preparation and uses thereof |
| 02/25/2009 | EP2027114A1 Maleate co-crystal of azd1152 |
| 02/25/2009 | EP2027109A1 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer |
| 02/25/2009 | EP2027107A1 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors |
| 02/25/2009 | EP2026842A1 N-terminal modified peg-trail, method for preparing and uses thereof |
| 02/25/2009 | EP2026809A2 Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives |
| 02/25/2009 | EP2026808A1 Combination therapy for the treatment of cancer |
| 02/25/2009 | EP2026805A1 Pharmaceutical combinations of diazole derivatives for cancer treatment |
| 02/25/2009 | EP2026800A1 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 02/25/2009 | EP2026797A2 Method for treating non-hodgkin's lymphoma |
| 02/25/2009 | EP2026789A2 Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum |
| 02/25/2009 | EP2026781A2 Pharmaceutical preparation based on myrtucommulone a for the selective tumour and cancer therapy |
| 02/25/2009 | EP2026780A1 Composition for the treatment of resistant cancers comprising oridonin |
| 02/25/2009 | EP2026775A2 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
| 02/25/2009 | EP2026654A2 Macrophage migration inhibitory factor antagonists and methods of using same |
| 02/25/2009 | EP1701939B1 Anthraquinone compounds as anti cancer compounds |
| 02/25/2009 | EP1572246B1 Novel compositions of magnetic particles covered with gem-bisphosphonate derivatives |
| 02/25/2009 | EP1536787A4 Imidazole alkaloids from lepidium meyenii and methods of usage |
| 02/25/2009 | EP1521752B1 Macrocycles for the treatment of cancer |
| 02/25/2009 | EP1506188B1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/25/2009 | EP1471920B1 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/25/2009 | EP1254106B1 Calcilytic compounds |
| 02/25/2009 | EP1240326B1 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify this receptor |
| 02/25/2009 | EP1143965B1 Carbocyclic potassium channel inhibitors |
| 02/25/2009 | EP1075277B1 Methods for detecting and inhibiting angiogenesis |
| 02/25/2009 | EP1027056B1 Alpha-ketoamide multicatalytic protease inhibitors |
| 02/25/2009 | EP0852587B1 Synthetic peptides that inhibit il-6 activity |
| 02/25/2009 | CN101374840A 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| 02/25/2009 | CN101374819A Aryl-substituted quinazolones and uses thereof |
| 02/25/2009 | CN101374818A Pyrimidine derivatives |
| 02/25/2009 | CN101374807A Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| 02/25/2009 | CN101374531A Use of hyaluronic acid as a carrier molecule for different classes of therapeutic active agents |
| 02/25/2009 | CN101374524A Combination of mTOR inhibitor and antipolate compound |
| 02/25/2009 | CN101374522A ANG2 and VEGF inhibitor combinations |
| 02/25/2009 | CN101374509A Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| 02/25/2009 | CN101372475A Aromatic heterocyclic substituted acardite derivative and use thereof |
| 02/25/2009 | CN101372471A Novel use of alkyl isourea compound and analogues thereof |
| 02/25/2009 | CN101371909A Medicine for treating carcinoma of stomach and preparation method thereof |
| 02/25/2009 | CN101371890A Medicaments composite for treating gland hyperplasia and breast cancer and preparation method thereof |
| 02/25/2009 | CN101371876A Method for extracting and preparing total polysaccharide of compound abnormal savda mature agent |
| 02/25/2009 | CN101371875A Method for extracting and preparing total saponin of compound abnormal savda mature agent |
| 02/25/2009 | CN101371868A Chinese medicine preparation for treating aplastic anemia |
| 02/25/2009 | CN101371857A Composite medicament for inhibiting tumor and preparation method thereof as well as technique field |
| 02/25/2009 | CN101371840A Novel use of vinetine and analogue thereof |
| 02/25/2009 | CN101371839A Novel use of bisbenzylisoquinoline alkaloids |
| 02/25/2009 | CN101371838A Novel uses of neferine and analogue thereof |
| 02/25/2009 | CN101371832A Medical use of triacetyl andrographolide as proinflammatory cytokine inhibitor |
| 02/25/2009 | CN101371821A Anti-cancer medicine composition containing metabolism-resistance medicament |
| 02/25/2009 | CN101371820A Anticancer sustained-release agent containing methotrexate potentiating agent |
| 02/25/2009 | CN101371708A Almond maize noodles |
| 02/25/2009 | CN101371676A Coffee containing anticancer foodstuff |
| 02/25/2009 | CN101371670A Almonds eight-piece crisp cookies |
| 02/25/2009 | CN100463916C Preparation of hemsleyadine-A and its use of preparing pharmaceutics against cancers |